S&P Futures
4,164.25 -11.50 (-0.28%) Dow Futures
34,128.00 -78.00 (-0.23%) Nasdaq Futures
12,743.00 -33.75 (-0.26%) Russell 2000 Futures
1,971.50 -7.80 (-0.39%) Crude Oil
77.69 +0.55 (+0.71%) Gold
1,897.10 +12.30 (+0.65%)
Takeda Pharmaceutical Company Limited (TAK)
After hours:
Chart Events
Performance Outlook
| Previous Close | 15.80 |
| Open | 15.78 |
| Bid | 0.00 x 4000 |
| Ask | 0.00 x 1200 |
| Day's Range | 15.77 - 15.94 |
| 52 Week Range | 12.28 - 16.30 |
| Volume | |
| Avg. Volume | 2,839,673 |
| Market Cap | 49.496B |
| Beta (5Y Monthly) | 0.75 |
| PE Ratio (TTM) | 30.27 |
| EPS (TTM) | 0.53 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.73 (5.60%) |
| Ex-Dividend Date | Mar 30, 2022 |
| 1y Target Est | 17.63 |
- Business Wire
U.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
OSAKA, Japan & CAMBRIDGE, Mass., February 03, 2023--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded use of TAKHZYRO® (lanadelumab-flyo) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in pediatric patients 2 to <12 years of age.1 Prior to today’s approval, the only approved routine prophylaxis treatment options for children 6 to <12 years of age requir
- Insider Monkey
Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2023 Earnings Call Transcript
Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2023 Earnings Call Transcript February 2, 2023 Christopher O’Reilly: Thank you for taking time out of your very busy schedule to join us for the FY 22 Q3 Earnings Announcement by Takeda. My name is O’Reilly, Head of IR. I’ll be the master of ceremony today. Before starting, I’d […]
- Benzinga
Takeda Reports 13% Fall In Nine Month Operating Profit, Keeps Annual Guidance Unchanged
Takeda Pharmaceutical Co Ltd (NYSE: TAK) reported a 13% drop in operating earnings to ¥401.9 billion for the nine months ending December. However, it reaffirmed its profit outlook for FY22. Operating profit for Q3 increased 21% (1% on constant currency) to ¥329.5 billion. Related: HUTCHMED Out Licenses Fruquintinib To Takeda Outside China. In December, Takeda agreed to shell out $4 billion to Nimbus Therapeutics for an allosteric tyrosine kinase 2 inhibitor for multiple autoimmune diseases. Reve
